MME CATHERINE BUFFET

Rhumatologue

RPPS 10001420974

📊 Reconnaissance scientifique : 28/100📝 156 articles publiés🇫🇷 Publications académiques françaises (5)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

28 articles ont été cités au moins 28fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment

Gastrointestinal endoscopy · 2010

📚 230 citations🎯 RCR 8.25Top 3% NIH

Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure

Hepatology (Baltimore, Md.) · 2004

📚 213 citations🎯 RCR 5.15Top 7% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Female sex is a protective factor for the progression of fibrosis in patients with chronic hepatitis C virus (HCV) infection. Experimental data suggest that estrogens may have an antifibrotic effect. The objective of this study was to evaluate the influence of past pregnancies, oral contraceptives, menopause, and hormone replacement therapy (HRT) on liver fibrosis progression in HCV–infected women. Four hundred seventy–two HCV–infected women received a survey regarding prior pregnancies, menopause, and the use of oral contraceptives and HRT. The impact of these variables on liver fibrosis and its progression were evaluated using multivariate analyses considering all putative confounding factors. Two hundred one women completed the survey (43% response rate), 157 of whom had an estimated date of HCV infection (96 postmenopausal women, 96 women with previous pregnancies, and 105 women with past use of oral contraceptives). Through multivariate analyses, the estimated rate of fibrosis progression was higher in postmenopausal ( P < .05) and nulliparous ( P = .02) women and was associated with greater histological activity ( P < .001). Prior use of oral contraceptives had no significant influence. Among postmenopausal women, the estimated rate of fibrosis progression (±SE) was lower in women who received HRT compared with untreated patients (0.099 ± 0.016 vs. 0.133 ± 0.006 METAVIR units/yr; P = .02) and was similar to that of premenopausal women (0.093 ± 0.012 METAVIR units/yr; P value not significant). In conclusion , menopause appears to be associated with accelerated liver fibrosis progression in HCV–infected women, an effect that may be prevented by HRT. Pregnancies may have a beneficial impact on the long–term progression of liver fibrosis. (Hepatology 2004;40:1426-1433.)

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)

Hepatology (Baltimore, Md.) · 2015

📚 109 citations🎯 RCR 3.31Top 14% NIH

Lire l'abstract Crossref ↓

Various critical events, liver related or not, occur in patients with compensated cirrhosis, but their respective burden remains to be prospectively assessed. The aim of this prospective cohort study involving 35 French centers was to capture the whole spectrum of complications occurring in compensated viral cirrhosis (VC) using competing risks analyses. Inclusion criteria were: histologically proven cirrhosis resulting from hepatitis C virus (HCV) or hepatitis B virus (HBV); Child‐Pugh A; and no previous hepatic complications. The cohort was considered as a multistate disease model, cumulative incidences (CumIs) of events were estimated in a competing risks framework. A total of 1,654 patients were enrolled from 2006 to 2012 (HCV, 1,308; HBV, 315; HCV‐HBV, 31). During a median follow‐up of 34 months, at least one liver nodule was detected in 271 patients, confirmed as hepatocellular carcinoma (HCC) in 128 (4‐year cumI: 10.5%) and cholangiocarcinoma in 3. HCC incidence was higher in HCV (4‐year cumI: 11.4% vs. 7.4%; P = 0.05). HCC fulfilled Milan criteria in 79.3%, leading to curative treatment in 70.4%. Liver decompensation occurred more frequently in HCV patients (4‐year cumI: 10.8% vs. 3.6%; P = 0.0004). Virological eradication/control was achieved in 34.1% of HCV and 88.6% of HBV patients and was associated with a marked decrease in HCC, decompensation, and bacterial infection incidences. Survival was shorter in HCV patients (4‐year cumI: 91.6% vs. 97.2%; P = 0.0002). Death (n = 102; missing data: 6) was attributed to liver disease in 48 (47%; liver cancer: n = 18; miscellaneous, n = 30) and extrahepatic causes in 48 (47%; bacterial infection: n = 13; extrahepatic cancers: n = 10; cardiovascular events: n = 5; miscellaneous, n = 20). Conclusion: After 3 years of follow‐up, extrahepatic events still explained half of deaths in patients with compensated VC. A strong decrease in complications was linked to virological eradication/control. (Hepatology 2015;62:737–750)

Cookies & analyse de trafic

MME CATHERINE BUFFET

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (2)

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal40

Essai clinique2

Pharmacovigilance2

Sclérodermie2

Vraie vie / RWE2

Épidémiologie & registres1

Lupus1

Revue générale1

Santé mentale / fatigue1

Partager cette fiche